Literature DB >> 2342578

Telomeres shorten during ageing of human fibroblasts.

C B Harley1, A B Futcher, C W Greider.   

Abstract

The terminus of a DNA helix has been called its Achilles' heel. Thus to prevent possible incomplete replication and instability of the termini of linear DNA, eukaryotic chromosomes end in characteristic repetitive DNA sequences within specialized structures called telomeres. In immortal cells, loss of telomeric DNA due to degradation or incomplete replication is apparently balanced by telomere elongation, which may involve de novo synthesis of additional repeats by novel DNA polymerase called telomerase. Such a polymerase has been recently detected in HeLa cells. It has been proposed that the finite doubling capacity of normal mammalian cells is due to a loss of telomeric DNA and eventual deletion of essential sequences. In yeast, the est1 mutation causes gradual loss of telomeric DNA and eventual cell death mimicking senescence in higher eukaryotic cells. Here, we show that the amount and length of telomeric DNA in human fibroblasts does in fact decrease as a function of serial passage during ageing in vitro and possibly in vivo. It is not known whether this loss of DNA has a causal role in senescence.

Entities:  

Mesh:

Year:  1990        PMID: 2342578     DOI: 10.1038/345458a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  1465 in total

1.  TIN2, a new regulator of telomere length in human cells.

Authors:  S H Kim; P Kaminker; J Campisi
Journal:  Nat Genet       Date:  1999-12       Impact factor: 38.330

2.  Inhibition of telomerase by 2'-O-(2-methoxyethyl) RNA oligomers: effect of length, phosphorothioate substitution and time inside cells.

Authors:  A N Elayadi; A Demieville; E V Wancewicz; B P Monia; D R Corey
Journal:  Nucleic Acids Res       Date:  2001-04-15       Impact factor: 16.971

3.  Telomere maintenance in telomerase-deficient mouse embryonic stem cells: characterization of an amplified telomeric DNA.

Authors:  H Niida; Y Shinkai; M P Hande; T Matsumoto; S Takehara; M Tachibana; M Oshimura; P M Lansdorp; Y Furuichi
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

4.  Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence.

Authors:  R V Lord; D Salonga; K D Danenberg; J H Peters; T R DeMeester; J M Park; J Johansson; K A Skinner; P Chandrasoma; S R DeMeester; C G Bremner; P I Tsai; P V Danenberg
Journal:  J Gastrointest Surg       Date:  2000 Mar-Apr       Impact factor: 3.452

Review 5.  Telomeres: the time factor in essential hypertension.

Authors:  A Aviv; W Zahorodny
Journal:  Curr Hypertens Rep       Date:  2001-02       Impact factor: 5.369

6.  Change of the death pathway in senescent human fibroblasts in response to DNA damage is caused by an inability to stabilize p53.

Authors:  A Seluanov; V Gorbunova; A Falcovitz; A Sigal; M Milyavsky; I Zurer; G Shohat; N Goldfinger; V Rotter
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

7.  Conditional immortalization of freshly isolated human mammary fibroblasts and endothelial cells.

Authors:  M J O'Hare; J Bond; C Clarke; Y Takeuchi; A J Atherton; C Berry; J Moody; A R Silver; D C Davies; A E Alsop; A M Neville; P S Jat
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-16       Impact factor: 11.205

8.  Functional requirement of p23 and Hsp90 in telomerase complexes.

Authors:  S E Holt; D L Aisner; J Baur; V M Tesmer; M Dy; M Ouellette; J B Trager; G B Morin; D O Toft; J W Shay; W E Wright; M A White
Journal:  Genes Dev       Date:  1999-04-01       Impact factor: 11.361

9.  Telomerase activity is sufficient to allow transformed cells to escape from crisis.

Authors:  T L Halvorsen; G Leibowitz; F Levine
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

10.  Telomere amount and length assay.

Authors:  Y Gan; K J Engelke; C A Brown; J L Au
Journal:  Pharm Res       Date:  2001-12       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.